Clinical data
Trade namesIncrelex
Other namesFK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1
License data
  • AU: B3
Routes of
Subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life5.8 hours[2]
CAS Number
  • none
Chemical and physical data
Molar mass7648.71 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[2][3][4]

Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[2]

A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[5] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[5]


  1. ^ "Summary Basis of Decision (SBD) for Increlex". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ a b c d "Increlex- mecasermin injection, solution". DailyMed. 7 May 2020. Retrieved 30 May 2022.
  3. ^ Fintini D, Brufani C, Cappa M (June 2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and Clinical Risk Management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
  4. ^ "Increlex". Retrieved 10 January 2010.
  5. ^ a b "IPLEXTM (mecasermin rinfabate [rDNA origin] injection) Package Insert" (PDF). U.S. Food and Drug Administration.